glucagon-like peptide-1 receptor agonists (GLP1 agonists) and erectile dysfunction (ED)
A study investigated the association between glucagon-like peptide-1 receptor agonists (GLP-1RAs) and the risk of erectile dysfunction (ED) in men with type 2 diabetes (T2D) (1):
- a target trial emulation using electronic health records from a U.S. health system between January 2019 and September 2024. Adult men (>18 years) with T2D initiating either GLP-1RA or DPP4i were included
- primary outcome was incident ED identified using diagnostic codes
The incidence rate of ED was higher in the GLP-1RA users (35.2 vs. 28.0 per 1000 person-years) than DPP4i users, with a slightly increased rate (HR, 1.26; 95% CI, 1.08–1.46).
Study authors concluded:
- in men with T2D, GLP-1RA use was modestly associated with an increased rate of ED
- observational findings may reflect residual or selection bias and do not establish causation
Reference:
- Tang H, Lu Y, Zhang B et al.GLP-1 receptor agonist and risk of erectile dysfunction in men with type 2 diabetes: a target trial emulation. eClinicalMedicine, 2026; 94.
Create an account to add page annotations
Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.